SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : After Glaxo's genital herpes vaccine flop, check out Agenus
GSK 46.86-0.2%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: robert b furman who wrote (15)1/24/2015 1:21:24 PM
From: albertaft  Read Replies (1) of 22
 
Hi Bob, I believe they're looking at approximately 30,000 doses on the next shipment, but have to verify that. Within 6 months by the summer time they will have enough to eradicate it. So we're look at around 6 months. Once the WHO gives the word that GSK's vaccine is the one to use, which should be within about 30 days, then that's when the big money will come in. At this point GSK is producing as much of the vax as possible as it's really the only vaccine available at the moment, with the exception of Merck, of which I haven't confirmed that they sent a shipment to W. Africa as of yet. Something may have gone wrong with theirs?

Ebola won't be eradicated without a vaccine for a very long time. They say the numbers are slowing, but wait until they venture into the remote areas where they will find huge die offs and thousands dead. With 22,000 cases they're only reporting 8600 fatalities. This Ebola has a fatality rate of 70% so there are around 7,000 dead bodies unaccounted for. The WHO has also estimated all numbers to be 2.5 times higher.

GSK's vaccine will have a key role in the fight against Ebola, and perhaps the most important one.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News